Look, J.J.LookWilhelm, N.N.WilhelmBriesen, H. vonH. vonBriesenNoske, N.N.NoskeGünther, C.C.GüntherLanger, K.K.LangerGorjup, E.E.Gorjup2022-03-052022-03-052015https://publica.fraunhofer.de/handle/publica/24220210.1021/acs.molpharmaceut.5b00153The development of nonviral gene delivery systems is a great challenge to enable safe gene therapy. In this study, ligand-modified nanopartides based on human serum albumin (HSA) were developed and optimized for an efficient gene therapy. Different glutaraldehyde cross-linking degrees were investigated to optimize the HSA nanopartides for gene delivery. The peptide sequence arginine-glycine-aspartate (RGD) and the HIV-1 transactivator of transduction sequence (Tat) are well-known as promising targeting ligands. Plasmid DNA loaded HSA nanopartides were covalently modified on their surface with these different ligands. The transfection potential of the obtained plasmid DNA loaded RGD-and Tat-modified nanopartides was investigated in vitro, and optimal incubation conditions for these preparations were studied. It turned out that Tat-modified HSA nanopartides with the lowest cross-linking degree of 20% showed the highest transfection potential. Taken together, ligand-functionalized represent promising tools for efficient and safe gene therapy. HSA nanopartidesen540journal article